Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome

Fertil Steril. 2009 Sep;92(3):1053-1058. doi: 10.1016/j.fertnstert.2008.07.1757. Epub 2008 Oct 18.

Abstract

Objective: To determine the effect of treatment with vitamin D(3) analogue in the parameters of glucose metabolism in obese women with polycystic ovary syndrome (PCOS).

Design: Observational study.

Setting: Obese women with PCOS in an academic research environment.

Patient(s): Fifteen obese women (mean age 28 +/- 1.3 years, mean body mass index 32.55 +/- 0.43) with documented chronic anovulation and hyperandrogenism were recruited into the study.

Intervention(s): Alphacalcidol (1-alpha-hydroxyvitamin D(3)) was administered orally 1 microg/day for 3 months. All subjects underwent a frequently sampled IV glucose tolerance test after a 10- to 12-hour overnight fast during a spontaneous bleeding episode before and after treatment with alphacalcidol.

Main outcome measure(s): Peripheral insulin resistance and insulin effectiveness were estimated with minimal model.

Result(s): The first phase of insulin secretion was significantly increased after treatment with alphacalcidol. A favorable statistically significant change also was observed in the lipid profile.

Conclusion(s): Treatment with the vitamin D(3) analogue (alphacalcidol) could be of value in the management of PCOS.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Blood Glucose / drug effects
  • Bone Density Conservation Agents / pharmacology
  • Bone Density Conservation Agents / therapeutic use
  • Calcium / blood
  • Dose-Response Relationship, Drug
  • Female
  • Glucose / metabolism*
  • Glucose Tolerance Test
  • Humans
  • Hydroxycholecalciferols / pharmacology
  • Hydroxycholecalciferols / therapeutic use
  • Insulin / blood
  • Insulin Resistance / physiology
  • Lipid Metabolism / drug effects
  • Obesity / metabolism
  • Obesity / physiopathology
  • Parathyroid Hormone / blood
  • Polycystic Ovary Syndrome / drug therapy
  • Polycystic Ovary Syndrome / metabolism*
  • Polycystic Ovary Syndrome / physiopathology*
  • Vitamin D / analogs & derivatives
  • Vitamin D / physiology*

Substances

  • Blood Glucose
  • Bone Density Conservation Agents
  • Hydroxycholecalciferols
  • Insulin
  • Parathyroid Hormone
  • Vitamin D
  • Glucose
  • Calcium
  • alfacalcidol